U.S. Markets closed

Puma Biotechnology (PBYI) in Focus: Stock Tumbles 18.3%

Zacks Equity Research

Puma Biotechnology, Inc. (PBYI) saw a big move last session, as the company’s shares fell by over 18% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading below the volatile price range of $122.06 to $103.96 in the past one-month time frame.

This biopharmaceutical company has seen a mixed track record when it comes to current year estimate revisions. However, the current year loss consensus has narrowed over the past few weeks. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump

PBYI currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Some better-ranked stocks in the Med-Biomed Generic sector include Alkermes plc (ALKS), Alexion Pharmaceuticals, Inc. (ALXN) and ANI Pharmaceuticals, Inc. (ANIP). All these stocks carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

PUMA BIOTECHNOLOGY INC (PBYI): Free Stock Analysis Report

ALKERMES PLC ORD (ALKS): Free Stock Analysis Report


ANI PHARMACEUTICALS INC (ANIP): Free Stock Analysis Report

Zacks Investment Research